InspireMD, Inc. (NSPR)
| Market Cap | 39.52M -61.2% |
| Revenue (ttm) | 10.84M +53.4% |
| Net Income | -52.48M |
| EPS | -0.65 |
| Shares Out | 46.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,225 |
| Open | 0.8757 |
| Previous Close | 0.8887 |
| Day's Range | 0.8300 - 0.8961 |
| 52-Week Range | 0.6300 - 2.5650 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 3.33 (+291.77%) |
| Earnings Date | Aug 17, 2026 |
About NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection syste... [Read more]
Financial Performance
In 2025, InspireMD's revenue was $8.98 million, an increase of 28.11% compared to the previous year's $7.01 million. Losses were -$48.79 million, 52.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NSPR stock is "Buy." The 12-month stock price target is $3.33, which is an increase of 291.77% from the latest price.
News
InspireMD Earnings Call Transcript: Q2 2026
Q2 2026 results were heavily impacted by a voluntary recall, leading to negative U.S. revenue and gross margin, but international sales grew 21% year-over-year. Regulatory progress continues, with key FDA approvals targeted for late 2026 and early 2027, and cost-saving measures are expected to be fully realized by Q4.
InspireMD Quarterly report: Q2 2026
InspireMD has published its Q2 2026 quarterly earnings report on August 17, 2026.
InspireMD Earnings release: Q2 2026
InspireMD released its Q2 2026 earnings on August 17, 2026, summarizing the period's financial results.
InspireMD reports Q2 EPS (17c), consensus (19c)
Reports Q2 revenue $1.77M, consensus $2.13M. “Following the end of the second quarter, we executed a series of steps designed to consolidate resources and better align our global operations with…
InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of th...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announce...
InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales Direct...
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...
InspireMD enrolls first patient in CGUARDIANS III study
InspireMD (NSPR) announced that the first patient has been enrolled in the CGUARDIANS III study of its SwitchGuard neuro protection system, for use with its CGuard Prime 80 cm stent…
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...
InspireMD Transcript: Bank of America Global Healthcare Conference 2026
Stroke prevention is shifting rapidly toward endovascular stenting, driven by strong clinical evidence and expanded coverage. The flagship stent demonstrates best-in-class outcomes and is now being commercialized in the U.S., with significant market growth expected.
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced...
InspireMD price target lowered to $3 from $4 at Piper Sandler
Piper Sandler analyst Adam Maeder lowered the firm’s price target on InspireMD (NSPR) to $3 from $4 and keeps an Overweight rating on the shares. The firm notes the company…
InspireMD reports Q1 EPS (16c), consensus (18c)
Reports Q1 revenue $3.4M, consensus $2.7M. “Our first quarter results reflect strong underlying demand and consistent clinical outcomes for our CGuard carotid stent implant both in the U.S. and intern...
InspireMD Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 122% year-over-year to $3.4M, driven by strong global demand, but U.S. commercialization paused due to technical issues with the CGuard Prime 135 delivery system. Full-year guidance was withdrawn, with FDA approval for relaunch targeted for Q3 2026.
InspireMD Earnings release: Q1 2026
InspireMD released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
InspireMD Quarterly report: Q1 2026
InspireMD has published its Q1 2026 quarterly earnings report on May 4, 2026.
InspireMD Reports First Quarter 2026 Financial Results
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro pr...
InspireMD Slides: Investor presentation
InspireMD has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
InspireMD price target lowered to $4 from $5 at Lake Street
Lake Street lowered the firm’s price target on InspireMD (NSPR) to $4 from $5 and keeps a Buy rating on the shares. InspireMD’s voluntary recall of the CGuard Prime 135…
InspireMD withdrawing prior FY26 revenue guidance
InspireMD (NSPR) announced that, in consultation with the U.S. Food and Drug Administration, the company has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid…
InspireMD initiates voluntary U.S. recall of CGuard Prime 135 cm system
InspireMD (NSPR) announced that, in consultation with the U.S. Food and Drug Administration, the company has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid…
InspireMD announces FDA approval of IDE application for CGUARDIANS III study
InspireMD (NSPR) announced that the U.S. FDA has approved the company’s Investigational Device Exemption Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection sy...
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% -
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced...